hypnomidate 2 mg/ml raztopina za injiciranje
janssen-cilag kft. - etomidat - raztopina za injiciranje - etomidat 2 mg / 1 ml - etomidat
hypnomidate 2 mg/ml raztopina za injiciranje
etomidat - raztopina za injiciranje - etomidat 2 mg / 1 ml - etomidat
etomidat-lipuro 2mg/ml emulzija za injiciranje
emulzija za injiciranje - etomidat
etomidat-lipuro 2 mg/ml emulzija za injiciranje
medis, d.o.o. - emulzija za injiciranje - etomidat
hypnomidate 2 mg/ml raztopina za injiciranje
kemofarmacija d.d. - raztopina za injiciranje - etomidat
temozolomide hexal
hexal ag - temozolomid - glioma; glioblastoma - antineoplastična sredstva - za zdravljenje odraslih bolnikov z novo diagnosticiranim multiformnim glioblastomom ob sočasnem radioterapiji (rt) in kasneje kot samostojno zdravljenje. za zdravljenje otroke, starejše od treh let, mladostniki in odrasli bolniki s malignega glioma, na primer glioblastomom multiforme anaplastični astrocitomi, ki prikazujejo, ponovitev ali napredovanje po standardni terapiji,.
repso
teva b.v. - leflunomid - arthritis, rheumatoid; arthritis, psoriatic - imunosupresivi - leflunomid je indiciran za zdravljenje odraslih bolnikov z:aktivni revmatoidni artritis kot "bolezni spreminjajo antirheumatic drog" (dmard);aktivnim psoriatičnim artritisom. nedavne ali sočasno zdravljenje z hepatotoxic ali haematotoxic dmards (e. metotreksat) lahko poveča tveganje za resne neželene učinke; zato je treba pri teh vidikih koristnosti / tveganja skrbno razmisliti o začetku zdravljenja z leflunomidom. poleg tega je prehod iz leflunomid na drugo dmard brez sledi postopek izpiranja lahko tudi poveča tveganje za resne neželene učinke, še dolgo po tem, ko je preklapljanje.
aubagio
sanofi winthrop industrie - teriflunomide - multiple skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi, selektivno imunosupresivi - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).